MACROGENICS INC
Close on Oct 19, 2026
- Market cap
- $211.77M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | $20.80M | $-0.58 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 9, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | After market close | $72.80M | $0.27 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | $22.20M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | After market close | $13.20M | $-0.65 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 20, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | After market close | $110.70M | $0.90 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | After market close | $10.80M | $-0.89 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | After market close | $9.10M | $-0.84 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | After market close | – | – | – |
Press releases
Announcements Macrogenics filed with the SEC
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
Results of operations · EX-99.1 to Form 8-K
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Other events · EX-99.1 to Form 8-K
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED CONSOLIDATED PRO FORMA FINANCIAL INFORMATION
Acquisition or disposition completed · Regulation FD disclosure · EX-99.2 to Form 8-K
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
Results of operations · EX-99.1 to Form 8-K
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
Other events · EX-99.1 to Form 8-K
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
Results of operations · EX-99.1 to Form 8-K
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
Other events · EX-99.1 to Form 8-K
MacroGenics Reports Third Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Reports Second Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Appoints Eric Risser as President and Chief Executive Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
Material agreement · Other events · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Scott Koenig, M.D., Ph.D., to step down as President and CEO
Executive or director change · Other events · EX-99.1 to Form 8-K
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Other events · EX-99.1 to Form 8-K
Developing Breakthrough Biologics, Life-changing Medicines® Post-ESMO Conference Call September 16, 2024
Other events · EX-99.2 to Form 8-K
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Provides Vobramitamab Duocarmazine Update
Other events · EX-99.1 to Form 8-K
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte
Other events · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data
Results of operations · EX-99.1 to Form 8-K
Developing Breakthrough Biologics, Life-changing Medicines® Phase 2 Interim Data May 9, 2024 (Data Cut-off: April 12, 2024)
Other events · EX-99.1 to Form 8-K
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
Other events · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress and Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress and First Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of ZYNYZ™ (retifanlimab-dlwr)
Other events · EX-99.1 to Form 8-K
MacroGenics Provides Corporate Update and 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Announces Sale of TZIELD ™ Royalty Interest for up to $200 Million
Material agreement · Other events · EX-99.1 to Form 8-K
MacroGenics Announces Appointment of Dr. Margaret Liu and Meenu Chhabra Karson to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
Other events · EX-99.1 to Form 8-K
MacroGenics Provides Corporate Update and Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Jacquie Ross, Investors Jim Karrels, Senior Vice President, CFO
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
MacroGenics Provides Update on Corporate Progress and Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer
Other events · EX-99.1 to Form 8-K